Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Peter Impey

- PMLiVE

AbbVie gains rights to FutureGen’s inflammatory bowel disease candidate in deal worth $1.7bn

The agreement gives AbbVie exclusive global rights to the TL1A-targeting monoclonal antibody

- PMLiVE

Bristol Myers Squibb’s Augtyro granted expanded FDA approval for solid tumours

The drug was approved by the US regulator last year to treat ROS1-positive NSCLC

- PMLiVE

Roche’s spinal muscular atrophy treatment Evrysdi shows continued benefit in children

The progressive neuromuscular disease affects approximately one in every 10,000 babies

- PMLiVE

Pfizer/Flagship’s drug discovery partnership to focus on obesity treatments

The agreement with Profound Therapeutics is the first to be initiated under the partnership

Can Cinderella save us?

KCL research could speed up discovery of new antibiotics in fight against AMR

According to WHO, AMR is designated as one of the top ten global public health threats facing humanity

- PMLiVE

Innovation in oncology

Iona Everson from PMGroup spoke to Jack Harris, Vice President of Oncology at GSK, about his career path and his drive to improve patient care

- PMLiVE

Men’s Health Week: The Power of Conversation

We're launching a number of schemes to help support men's mental health throughout the year. This Men's Health Week, make sure you check out some of our plans.

Mednet Group

Maximizing KOL Engagement with Asynchronous Tools

Dive into the variety of asynchronous tools available on the Impetus InSite Platform® with our ninth tip. Learn how different tools can enhance your virtual touchpoints and elevate the quality...

Impetus Digital

- PMLiVE

AstraZeneca’s Farxiga granted FDA approval to treat type 2 diabetes in paediatric patients

The chronic disease currently affects almost 30,000 people aged under 20 years in the US

- PMLiVE

Roche enters licensing agreement with ALZpath to advance Alzheimer’s blood test

The agreement will leverage ALZpath’s pTau217 antibody and Roche’s Elecsys platform

- PMLiVE

Eli Lilly’s GIP/GLP-1 receptor agonist tirzepatide shows promise in fatty liver disease MASH

Metabolic dysfunction-associated steatohepatitis is the second most common contributor to liver transplantation in the US

- PMLiVE

GSK and Ochre Bio enter multi-year partnership to investigate liver disease drivers

There are more than 10,000 deaths due to liver disease each year in the UK

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links